A phase II study of anti-CD52 monoclonal antibody (Alemtuzumab, MabCampath) with 2-weekly CHOP chemotherapy (Camp-CHOP 14) in patients with mature T-cell non-Hodgkins lymphoma.

Trial Profile

A phase II study of anti-CD52 monoclonal antibody (Alemtuzumab, MabCampath) with 2-weekly CHOP chemotherapy (Camp-CHOP 14) in patients with mature T-cell non-Hodgkins lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2013

At a glance

  • Drugs Alemtuzumab; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Prednisolone; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma; T cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jul 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top